肠道铁调素过表达通过下调DMT1促进缺铁性贫血并对抗铁过载
研究通过构建肠道特异性过表达铁调素的转基因小鼠,发现1月龄时小鼠出现严重缺铁、血液学指标下降及肝铁调素显著抑制;机制上肠道铁调素在肠腔产生并显著下调肠上皮细胞DMT1蛋白;进一步用食品级重组乳酸菌递送铁调素,可快速降低十二指肠DMT1并保护血色病小鼠模型对抗铁过载。
要点
- 肠道特异性过表达铁调素的小鼠在1月龄出现严重缺铁及血液学指标下降。
- 肠道铁调素在肠腔产生并显著下调肠上皮细胞DMT1蛋白。
- 口服递送铁调素的重组乳酸菌可降低十二指肠DMT1并保护血色病小鼠对抗铁过载。
核心结论
- 肠道铁调素作为系统铁稳态的调节因子,作用于肠上皮细胞顶侧DMT1,对血液或铁相关疾病具有潜在治疗意义。
研究设计与样本
- 研究生成肠道特异性过表达铁调素的转基因小鼠,并开发食品级重组乳酸菌(recLAB)将铁调素直接递送至肠腔,在血色病小鼠模型中进行口服给药评估。
主要发现
- 转基因小鼠在1月龄时表现出严重缺铁,伴随血液学指标下降及对低铁血症应答的肝铁调素急剧抑制。
- 肠道铁调素在肠腔产生,诱导肠上皮细胞DMT1蛋白显著下调。
- 重组乳酸菌可快速降低十二指肠DMT1,每日口服给药可保护血色病小鼠模型对抗铁过载。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepcidin is the key hyposideremic hormone produced primarily by the liver. However, recent reports reveal extrahepatic functional sources of hepcidin, including the intestine, the site of dietary iron absorption. To determine whether intestinal hepcidin may play a role in plasma iron lowering, we generated transgenic mice overexpressing the peptide specifically in this tissue. At 1 month of age, transgenic mice exhibited severe iron deficiency along with decreased hematologic indices and a drastic suppression of liver hepcidin in response to hyposideremia. Mechanistically, we showed that intestinal hepcidin was produced in the intestine lumen, inducing a striking downregulation of divalent metal transporter 1 (DMT1) protein at the enterocyte. To confirm the capacity of hepcidin to decrease DMT1, we developed food-grade recombinant lactic acid bacteria (recLAB) genetically modified to deliver hepcidin directly into the intestinal lumen. These recLAB induced a rapid decrease of duodenal DMT1 and, most importantly, when daily orally administrated, protected against iron overload in a mouse model of hemochromatosis. Taken together, our data reveal a previously unrecognized role of intestinal hepcidin as a regulator of systemic iron homeostasis, acting on DMT1 on the apical side of enterocytes, with potential therapeutic relevance for hematologic or iron disorders.
引用
- Falabrègue M, Aurrand C, Cazaulon L, et al. Intestinal hepcidin overexpression promotes iron deficiency anemia and counteracts iron overload via DMT1 downregulation. Blood. 2025. PMID: 40925095. doi:10.1182/blood.2025028370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。